Matches in DBpedia 2016-04 for { ?s ?p "Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers. It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).This drug is being developed by Pfizer and UCB.It is undergoing numerous clinical trials, including two phase II trials for Non-Hodgkin lymphoma (NHL)."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Inotuzumab_ozogamicin comment "Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers. It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).This drug is being developed by Pfizer and UCB.It is undergoing numerous clinical trials, including two phase II trials for Non-Hodgkin lymphoma (NHL).".
- Q3799041 comment "Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers. It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).This drug is being developed by Pfizer and UCB.It is undergoing numerous clinical trials, including two phase II trials for Non-Hodgkin lymphoma (NHL).".